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Abstract: The fat mass and obesity associated (FTO) gene has an important genetic effect on body mass index (BMI) and risk of obesity, 
and obesity contributes to the progression of renal diseases, including diabetic nephropathy. We thus conducted a genetic   association study 
to evaluate whether the FTO gene confers the risk susceptibility to the development of diabetic nephropathy.   Genotyping   experiments 
of the common FTO polymorphism, rs9939609, in 1170 type 1 diabetes patients with (n = 597) or without diabetic   nephropathy 
(n = 573) were performed with TaqMan allelic discrimination. All subjects are of European descent and selected from the Genetics of 
Kidney Diseases in Diabetes (GoKinD) study. The frequency of T allele of this polymorphism was 0.414 in the studied population. 
There was no allelic association of this polymorphism with diabetic nephropathy. But, the risk susceptibility of A allele conferring to the 
increased BMI among type 1 diabetes patients was observed. The subjects carrying with AA genotype had higher BMI compared to the 
carriers with TA and/or TT genotype(s) (P # 0.019). The present study provides evidence that the common FTO genetic polymorphism, 
rs9939609, is associated with increased BMI in type 1 diabetes but not with diabetic nephropathy.
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Introduction
Obesity, associated with insulin resistance, is a core 
component of the metabolic syndrome, and is among 
the top ten global health risks classified by the World 
Health Organization (WHO). Current evidence has 
demonstrated that obesity is associated with the early 
onset of glomerulomegaly, hemodynamic changes of a 
hyperfiltering kidney and increased albuminuria.1–3 In 
patients with chronic kidney disease (CKD),   variation 
of  proteinuria  is  associated  with  body  mass  index 
(BMI).4 Thus, obesity contributes to the progression 
of renal diseases, including diabetic nephropathy.
In  the  recent  two  years,  several  genome-wide 
  association  (GWA)  studies  have  indicated  that  the 
fat mass and obesity associated (FTO) gene has an 
  important genetic effect on BMI and risk of   obesity. 
A  common  genetic  polymorphism,  rs9939609,  in 
the FTO gene is found to associate with BMI and 
  predisposes to   childhood and adult obesity. Rs9939609 
is an intronic single nucleotide   polymorphism (SNP, 
the code is W = A/T) and resides in the first intron of 
the gene. The AA homozygous genotype results in an 
average increase of ∼3 kg in body weight or one BMI 
unit in the subjects compared to the TT genotype.5–8 
  Obviously,  this  FTO  variant  is  involved  in  the 
  pathogenesis of obesity. However, it is unclear whether 
the FTO gene confers the risk   susceptibility to the 
development of diabetic nephropathy.   Therefore, it is 
necessary to carry out a genetic study of the FTO gene 
in diabetic   nephropathy. In the present study, we have 
conducted a genetic association study of this FTO 
genetic   polymorphism with diabetic   nephropathy in 
type 1 diabetes using a   well-characterized   material 




A total of 1170 type 1 diabetes patients with (n = 597) or 
without diabetic nephropathy (n = 573) were included 
in  the  present  study. All  subjects  are  of    European 
descent and selected from the GoKinD study.9 The 
patients  with  diabetic  nephropathy  had  persistent 
  proteinuria or end-stage renal disease (ESRD) for at 
least 10 years. Persistent proteinuria was defined as 2 
out of 3 tests of Urine Albumin/Urine Creatinine Ratio 
(ACR) value exceeding 300 µg albumin/mg of urine 
creatinine. The study was approved with the local eth-
ics committees. Data and material transfer agreements 
were  completed  prior  to  the  study.    Information  of 
clinical characteristics of the subjects is available as 
described in the previous reports.9,10
genotyping experiments
We have genotyped the common FTO polymorphism, 
rs9939609,  with  a  standard  protocol  of    TaqMan 
allelic discrimination. The assay and instrument used 
for allelic discrimination in genotyping experiments 
was purchased from Applied Biosystems (ABI 7300, 
Foster City, USA). For quality control, the subjects 
were  distributed  randomly  across  the  plates  with 
equal numbers of cases and controls on each PCR 
plate. Negative controls (Universal-mixture blanks) 
were included on each plate. Genotyping experiments 
in approximately 20% of samples were performed in 
duplicate. Successful genotype calls were ∼98% and 
duplication accuracy 100%.
statistical analyses
Proportions  of  genotypes  or  frequencies  of  alleles 
between the cases and controls were compared using a 
Chi-square (χ2) test. P-values ,0.05 were   considered 
as significant. Armitage’s trend,   additive and   dominant 
model  tests  were  performed.  Odds  ratios  (OR)  and 
95% confidence intervals (CI) were   calculated to test 
the relative risk for association. The sample sizes in the 
GoKinD populations had ∼90% power (at the 5% level) 
  assuming MAFs of 0.15.   Statistical   powers were calcu-
lated using software of   PowerSampleSize (PS   version 
2.1.31). Clinical data are expressed as mean ± SD. 
Analysis of   variance (one-way or two-way ANOVA) 
or   covariance was performed to   investigate differences 
of   clinical   parameters   according to   genotyes or groups. 
Non-normally    distributed  traits  (plasma    cystatin  C, 
serum  creatinine  and  BMI)  were    transformed  into 
  natural logarithms before analysis. All analyses were 
  performed using STATISTICA   version 7.1 (Statsoft, 
Tulsa, USA).
Results and Discussion
We have performed a genetic association analysis of 
the common FTO genetic polymorphism rs9939609 
in the GoKinD population and the genotype distribu-
tion is presented in Table 1. Data indicated that geno-
type distribution for this FTO genetic polymorphism 
was kept in Hardy-Weinberg equilibrium (P = ∼0.4). FTO and diabetic nephropathy
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The frequency of minor allele (MAF) A was 0.414 in 
the studied population, and no significant difference of 
the MAFs between type 1 diabetes patients with and 
without diabetic nephropathy was found (0.411 vs. 
0.416, P-values were 0.796, test with additive model, 
and 0.415, test for allele positivity, respectively).
We further analyzed clinical parameters   according 
to  the  TT,  TA  and  AA  genotypes  of  this  FTO 
  polymorphism. Results are summarized in Table 2 
and indicated that the overall type 1 diabetes   subjects 
carrying  with  TT,  AT  and  AA  genotypes  have 
  significantly and gradually increased BMI (P = 0.019, 
ANOVA test; and 0.008, the comparison between TT 
and AA).   Further analyses of cystatin and   creatinine 
levels among the subjects carrying with TT, AT and 
AA genotypes with or without adjustment for BMI 
and/or  age  were  performed.  But,  no  significant 
  difference was seen.
We have carried out a genetic association study of 
the common FTO genetic polymorphism, rs9939609, 
in  diabetic  nephropathy.  Although  there  was  no 
  significant  association  between  this    polymorphism 
and diabetic nephropathy, type 1   diabetes patients 
  carrying with AA genotype had significantly increased 
BMI compared to the patients with TT and/or AT 
genotype(s). Evidence has   indicated that increased 
BMI may increase the risk for the   development of 
  diabetic  nephropathy  in  type  1    diabetes.11  Recent 
genetic association studies have demonstrated that 
the  FTO  genetic  polymorphism  has  no  genetic 
effect  on  type  1  diabetes  when  the  comparison 
analysis between type 1 diabetes patients and non-
diabetic  controls  is  performed.12  Furthermore,  this 
FTO   polymorphism has been identified to confer an 
increased risk for both type 2 diabetes and obesity. 
After adjustment for BMI, however, the association 
with type 2 diabetes is vanished because the impact 
of  FTO  on  type  2  diabetes  is  mainly  due  to  the 
association of FTO with BMI.5 Therefore, the pres-
ent study provides evidence that the common FTO 
genetic  polymorphism,  rs9939609,  is  associated 
with increased BMI in type 1 diabetes but not with 
diabetic  nephropathy.  Taking  together  with  other 
reports5–8,11,12 and the present study, we conclude that 
the common FTO genetic polymorphism, rs9939609, 
confers the risk susceptibility to the increasing BMI, 
but not   fundamentally contributes to the   development 
of diabetic nephropathy.
Table 1. genotype distribution of rs9939609 in UsA goKinD population.
Group n TT TA AA MAF(%) P-value
Overall 1170 401 570 199 41.4
T1D with Dn 597 198 301 98 41.6
T1D without Dn 573 203 269 101 41.1 0.796a/0.415b
aTests for genetic association were performed with an additive model.
bor for allele positivity.
Abbreviations: T1D, Type 1 diabetes; Dn, Diabetic nephropathy; MAF, Minor Allele Frequency.
Table 2. clinical parameters according to the genotypes of rs9939609.
parameter Group TT TA AA P-value
BMI (kg/m2) Overall 25.34 ± 4.34 26.03 ± 4.99 26.43 ± 5.20 0.019c/0.008d
T1D without Dn 25.42 ± 3.65 26.35 ± 4.75 26.36 ± 4.38 0.055c/0.056d
T1D with Dn 25.25 ± 4.93 25.67 ± 5.23 26.50 ± 5.91 0.060c/0.057d
cystatin (mg/L) Overall   1.51 ± 1.34   1.56 ± 1.40   1.58 ± 1.47 0.826c/0.567d
T1D without Dn   0.81 ± 0.13   0.81 ± 0.14   0.81 ± 0.13 0.932c/0.832d
T1D with Dn   2.20 ± 1.60   2.36 ± 1.67   2.35 ± 1.77 0.580c/0.454d
creatinine (mg/dL) Overall   1.50 ± 1.43   1.50 ± 1.45   1.51 ± 1.39 0.997c/0.913d
T1D without Dn   0.90 ± 0.16   0.89 ± 0.16   0.88 ± 0.16 0.603c/0.608d
T1D with Dn   2.10 ± 1.84   2.18 ± 1.88   2.13 ± 1.76 0.908c/0.882d
cTests for phenotype difference were done with AnOVA.
dor by the comparison between TT and AA.
Abbreviations: T1D, Type 1 diabetes; Dn, Diabetic nephropathy. Data of clinical parameters are mean ± sD.publish with Libertas Academica and 
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